報價延遲最少15分鐘:2026/04/23 02:45 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.02/0.13
|
|
企業價值
1.16B
|
| 資產負債 |
|
每股賬面淨值
-0.17
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
348.97M
|
|
每股收益
0.57
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Companyis currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. |
